| Project/Area Number |
24592384
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HANADA Eiki 滋賀医科大学, 医学部, 助教 (40555067)
ARAKI Isao 滋賀医科大学, 医学部, 客員教授 (50252424)
YOSHIKI Tatsuhiro 滋賀医科大学, 医学部, 客員教授 (80230704)
|
|---|
| Research Collaborator |
KAWAUCHI Akihiro 滋賀医科大学, 医学部, 教授 (90240952)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | γ-グルタミルシクロトランスフェラーゼ / RNA干渉 / 尿路上皮癌 / siRNA / GGCT / 癌治療 / C7orf24 |
|---|
| Outline of Final Research Achievements |
We evaluated a utility of GGCT targeting therapy with RNAi for urothelial cancer.
In immunohistochemical analysis of surgical specimens of non-muscle invasive bladder cancer, high expression was revealed in 64% of the patients. The five-year recurrence free survivals of high and low-no GGCT expression groups were 30% and 57%, respectively. Significant antiprolifelative effect via GGCT targeting siRNA was shown in UMUC-3 cells, and combination treatment consisting of Adriamycin and GGCT siRNA reduced cell viability more than the treatment with Adriamycin alone. According to our results, GGCT can be a useful treatment target with RNAi for urothelial cancer. We continue the treatment experiment of tumor-bearing mice by administration GGCT siRNA, and evaluate therapeutic effects and adverse events.
|
